(Yicai) Nov. 3 -- Shares of Berry Genomics rose after the leading Chinese genomics services provider said China gave the green light to its subsidiary's third-generation gene sequencer, making it the first device of its kind approved for clinical use in the country.

Berry Genomics [SHE: 000710] closed 6.1 percent higher at CNY13.89 (USD1.95) a share today, after jumping by the 10 percent daily trading limit at one point. The broader Shenzhen market climbed 0.2 percent. 

The sequencer uses single-molecule real-time sequencing technology, Berry Genomics said late on Oct. 31, noting that it can assist in the diagnosis of genetic diseases or disease susceptibility by sequencing deoxyribonucleic acid from human samples in clinical settings.

Berry Genomics has independently produced testing reagents for the gene-sequencing equipment and is offering full-process localized service from data detection to report interpretation, the Beijing-based company noted.

The large-scale application of the third-gen sequencing tech will promote the rapid advancement of major public health projects such as birth defect prevention and control in China and even worldwide, Berry Genomics said. The firm will further lower the threshold for tech application by optimizing artificial intelligence algorithms and improving local deployment solutions to enable more families to enjoy more accurate, efficient, and economical testing services, it pointed out.

Compared with the first two generations of the tech, the latest gene sequencer can interpret the genetic information of specific genes more accurately and also significantly shorten the testing cycle, thanks to achieving full-process localized services from sample processing, sequencing, to report interpretation, according to Berry Genomics.

Editor: Martin Kadiev